nach oben

08.09.2015 | Zertifizierte Fortbildung | Ausgabe 9/2015

Vermutlich oft gesehen, aber nur selten diagnostiziert

Neurologische und psychiatrische Symptome der systemischen MCAD

Zeitschrift:: NeuroTransmitter > Ausgabe 9/2015

Autoren:: Dr. med. Dieter Pöhlau, Prof. Dr. med. Martin Raithel, PD Dr. rer. nat. Britta Haenisch, Dipl.-Phys. Sabrina Harzer, Prof. Dr. med. Gerhard J. Molderings

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Zusammenfassung

In der Neurologie und Psychiatrie finden sich oft Patienten mit zentralnervösen Symptomen, die dauerhaft oder episodisch unter vielen anderen Beschwerden leiden, deren Ursache trotz umfangreicher Suche unklar bleibt und deren symptomatische Therapien weitgehend frustran verlaufen. Eine systemische Mastzellaktivierungserkrankung (MCAD) wird nur selten in die differenzialdiagnostischen Überlegungen einbezogen.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Gri G, Frossi B, D’Inca F, Danelli L, Betto E, Mion F, Sibilano R, Pucillo C. Mast cell: an emerging partner in immune interaction. Front Immunol 2012;3:120. PubMedCentralCrossRefPubMed

Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. Cell Mol Life Sci 2011;68:965–75. CrossRefPubMed

Theoharides TC. The mast cell: a neuroimmunoendocrine master player. Int J Tissue React 1996;18:1–21. PubMed

Silverman AJ, Sutherland AK, Wilhelm M, Silver R. Mast cells migrate from blood to brain. J Neurosci 2000;20:401–8. PubMed

Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman AJ. Brain mast cell relationship to neurovasculature during development. Brain Res 2007;1171:18–29. PubMedCentralCrossRefPubMed

Porzionato A, Macchi V, Parenti A, De Caro R. The distribution of mast cells in the human area postrema. J Anat;204:141–7.

Turygin VV, Babik TM, Boyakov AA. Characteristics of mast cells in the choroid plexus of the ventricles of the human brain in aging. Neurosci Behav Physiol 2005;35:909–11. CrossRefPubMed

Maslinska D, Laure-Kamionowska M, Gujski M, Ciurzynska G, Wojtecka-Lukasik E. Post-infectional distribution and phenotype of mast cells penetrating human brains. Inflamm Res 2005; 54, Suppl.1:15–16. CrossRef

Pang X, Letourneau R, Rozniecki JJ, Wang L, Theoharides TC. Definitive characterization of rat hypothalamic mast cells. Neuroscience 1996;73:889–902. CrossRefPubMed

10.

Shanas U, Bhasin R, Sutherland AK, Silverman AJ, Silver R. Brain mast cells lack the c-kit receptor: immunocytochemical evidence. J Neuroimmunol 1998;90:207–11. CrossRefPubMed

11.

Dubayle D, Malissin I, Menetrey D. Differential effects of two analegesic drugs, morphine, chlorhydrate and acetylsalicylic acid, on thalamic mast cell numbers in rat. J Neuroimmunol 2005;169:106–15. CrossRefPubMed

12.

Kovacs P, Hernadi I, Wilhelm M. Mast cells modulate maintained neuronal activity in the thalamus in vivo. J Neuroimmunol 2006;171:1–7. CrossRefPubMed

13.

Ito A, Hagiyama M, Oonuma J. Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J Smooth Muscle Res 2008;44:83–93. CrossRefPubMed

14.

Nautiyal KM, McKellar H, Silverman AJ, Silver R. Mast cells are necessary for the hypothermic response to LPS-induced sepsis. Am J Physiol Regul Integr Comp Physiol 2009;296: R595–R602. PubMedCentralCrossRefPubMed

15.

Goldschmidt RC, Hough LB, Glick SD. Rat brain mast cells: contribution to brain histamine levels. J Neurochem 1985;44:1943–7. CrossRefPubMed

16.

Zarrindast MR, Valizadegan F, Rostami P, Rezayof A. Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats. Eur J Pharmacol 2008;583:108–14. CrossRefPubMed

17.

Dere E, Zlomuzica A, De Souza-Silva MA, Ruocco LA, Sadile AG, Huston JP. Neuronal histamine and the interplay of memory, reinforcement and emotions. Behav Brain Res 2010;215:209–20. CrossRefPubMed

18.

Gianlorenço AC, Serafim KR, Canto-de-Souza A, Mattioli R. Emotional memory consolidation impairment induced by histamine is mediated by H(1) but not H(2) receptors. Brain Res Bull 2012; 89:197–202. CrossRefPubMed

19.

Asadi S, Zhang B, Alysandratos K, Angelidou A, Vasiadi M, Theoharides T. Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Allergy Clin Immunol 2011;127, Suppl 2:AB162. CrossRef

20.

Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, Critchfield A, Theoharides TC. Neurotensin and CRH interactions augment human mast cell activation. PLoS One 2012;7:e48934. PubMedCentralCrossRefPubMed

21.

Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-a. PLoS One 2012;7:e39935. PubMedCentralCrossRefPubMed

22.

Theoharides TC, Petra AI, Stewart JM, Tsilioni I, Panagiotidou S, Akin C. High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. J Allergy Clin Immunol 2014;134:1197–9. CrossRefPubMed

23.

Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008;123:398–410. PubMedCentralCrossRefPubMed

24.

Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmächer T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445–52. CrossRefPubMed

25.

McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009;33:355–66. CrossRefPubMed

26.

Costa-Pinto FA, Basso AS, de Sa-Rocha LC, Britto LRG, Russo M, Palermo-Neto J. Neural correlates of IgE-mediated allergy. NY Acad Sci 2006;1088:116–31. CrossRef

27.

Nautiyal KM. Mast cells affect brain physiology and behaviour. 2011, Thesis.

28.

Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. Trends Neurosci 2013;36:513–21. CrossRefPubMed

29.

Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014;141:314–27. PubMedCentralCrossRefPubMed

30.

Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J, Hendrix S. The role of mast cells in neuroinflammation. Acta Neuropathol 2013;125:637–50. CrossRefPubMed

31.

Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, Sandkühler J. Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain 2011;7:42. PubMedCentralCrossRefPubMed

32.

Héron A, Dubayle D. A focus on mast cells and pain. J Neuroimmunol 2013;264:1–7. CrossRefPubMed

33.

Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One 2013;8:e60529. PubMedCentralCrossRefPubMed

34.

Molderings GJ, Homann J, Brettner S, Raithel M, Frieling T. Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. Dtsch Med Wochenschr. 2014;139:1523–34 CrossRefPubMed

35.

Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 2011;4:10. PubMedCentralCrossRefPubMed

36.

Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. PLoS One 2013;8:e76241. PubMedCentralCrossRefPubMed

37.

Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia - new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006;19: 5–9. PubMed

38.

Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29:1403–12. CrossRefPubMed

39.

Maeshima E, Furukawa K. A case of fibromyalgia syndrome with anaphylaxis induced by intradermal injection of purified protein derivative. Mod Rheumatol 2013;23:593–6. CrossRefPubMed

40.

Santos J, Guilarte M, Alonso C, Malagelada JR. Pathogenesis of irritable bowel syndrome: the mast cell connection. Scand J Gastroenterol 2005;40:129–40. CrossRefPubMed

41.

Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213–21. CrossRefPubMed

42.

Frieling T, Meis K, Kolck UW, Homann J, Hülsdonk A, Haars U, Hertfelder HJ, Oldenburg J, Seidel H, Molderings GJ. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 2011;49:191–4. CrossRefPubMed

43.

Haenisch B, Nöthen MM, Molderings GJ. Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology 2012;137:197–205. PubMedCentralCrossRefPubMed

44.

Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727–36. CrossRefPubMed

45.

Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A. Case-control cohort study of patients’ perceptions of disability in mastocytosis. PLoS ONE 2008;3:e2266. PubMedCentralCrossRefPubMed

46.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS ONE 2011;6:e26375. PubMedCentralCrossRefPubMed

47.

Moura DS, Sultan S, Georgin-Lavialle S, Barete S, Lortholary O, Gaillard R, Hermine O. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS ONE 2012;7:e39468. PubMedCentralCrossRefPubMed

48.

Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, Austen KF. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986;48: 437–47. CrossRefPubMed

49.

Tajima Y, Hamada K, Houzenn H. Sequential magnetic resonance features of encephalopathy induced by systemic mastocytosis. Intern Med 1994;33:23–6. CrossRefPubMed

50.

Jost E, Michaux L, Vanden Abeele M, Boland B, Latinne D, Godfraind C, Scheiff JM, Vaerman JL, Lecouvet F, Ferrant A. Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia, and brain damage. Ann Hematol 2001;80:302–7. CrossRefPubMed

51.

Boncoraglio GB, Brucato A, Carriero MR, Maccagnano E, Robbiolo L, Scappatura LO, Soligo D, Parati EA. Systemic mastocytosis: a potential neurologic emergency. Neurology 2005;65:332–333. CrossRefPubMed

52.

Smith JH, Butterfield JH, Pardanani A, Deluca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg 2011;113:570–4. CrossRefPubMed

53.

Afrin LB. Sclerosing mediastinitis and mast cell activation syndrome. Pathol Res Pract 2012;208:181–5. CrossRefPubMed

54.

Kushnir-Sukhov NM, Brittain E, Scott L, Metcalfe DD. Clinical correlates of blood serotonin levels in patients with mastocytosis. Eur J Clin Invest 2008;38:953–8. PubMedCentralCrossRefPubMed

55.

Georgin-Lavialle S, Moura DS, Bruneau J, Chauvet-Gélinier JC, Damaj G, Soucie E, Barete S, Gacon AL, Grandpeix-Guyodo C, Suarez F, Launay JM, Durieu I, Esparcieux A, Guichard I, Sparsa A, Nicolini F, Gennes CD, Trojak B, Haffen E, Vandel P, Lortholary O, Dubreuil P, Bonin B, Sultan S, Teyssier JR, Hermine O. Leukocyte telomere length in mastocytosis: Correlations with depression and perceived stress. Brain Behav Immun 2014;35:51–7. CrossRefPubMed

56.

Ashina S, Ashina M. Headache in systemic mastocytosis: a case report with pathophysiological considerations. Cephalalgia 2004;25:314–6. CrossRef

57.

Maintz L, Wardelmann E, Walgenbach K, Fimmers R, Bieber T, Raap U, Novak N. Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis. Allergy 2011;66:862–9. CrossRefPubMed

58.

Peng WM, Maintz L, Allam JP, Raap U, Gütgemann I, Kirfel J, Wardelmann E, Perner S, Zhao W, Fimmers R, Walgenbach K, Oldenburg J, Schwartz LB, Novak N. Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. Blood 2013;122:1779–88. CrossRefPubMed

59.

Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980;69:663–7. PubMedCentralCrossRefPubMed

60.

Haenisch B, Huber M, Wilhelm T, Steffens M, Molderings GJ. Investigation into mechanisms mediating the inhibitory effect of 1,4-benzodiazepines on mast cells by gene expression profiling. Life Sci 2013;92:345–51. CrossRefPubMed

61.

Hoffmann K, Xifró RA, Hartweg JL, Spitzlei P, Meis K, Molderings GJ, von Kügelgen I. Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells. Eur J Pharmacol 2013;700:152–8. CrossRefPubMed

62.

Yousefi OS, Wilhelm T, Maschke-Neuß K, Kuhny M, Martin C, Molderings GJ, Kratz F, Hildenbrand B, Huber M. The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions. Cell Commun Signal 2013;11:13. PubMedCentralCrossRefPubMed

63.

Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk of autism - review and proposal. BMC Pediatr 2012;12:89. PubMedCentralCrossRefPubMed

64.

Theoharides TC. Is a Subtype of Autism an Allergy of the Brain? Clin Ther 2013;35:584–91. CrossRefPubMed

65.

Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, Sonders MS, Kanter E, Castagna C, Yamamoto A, Yue Z, Arancio O, Peterson BS, Champagne F, Dwork AJ, Goldman J, Sulzer D. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014;83:1–13 CrossRef

66.

Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 2005;49:65–76. CrossRefPubMed

67.

Levy D, Burstein R, Strassman AM. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 2006;46 Suppl 1:S13–S18. CrossRefPubMed

68.

Yeom JS, Choi MB, Seo JH, Park JS, Lim JY, Park CH, Woo HO, Youn HS, Ko GH, Baik SC, Lee WK, Cho MJ, Rhee KH. Relationship between headache and mucosal mast cells in pediatric Helicobacter pylori-negative functional dyspepsia. Cephalalgia 2013;33:323–9. CrossRefPubMed

69.

Smith JH, Butterfield JH, Cutrer FM. Primary headache syndromes in systemic mastocytosis. Cephalalgia 2011;31:1522–31. CrossRefPubMed

70.

Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 2012;26:3103–17. CrossRefPubMed

71.

Yasuda M, Kido K, Ohtani N, Masaki E. Mast cell stabilization promotes antinociceptive effects in a mouse model of postoperative pain. J Pain Res 2013;6:161–6. PubMedCentralPubMed

72.

Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology 2012;116:882–95. PubMedCentralCrossRefPubMed

73.

Dirckx M, Groeneweg G, van Daele PL, Stronks DL, Huygen FJ. Mast Cells: A New arget in the Treatment of Complex Regional Pain Syndrome? Pain Pract 2013;13:599–603. CrossRefPubMed

74.

Riccardi VM. Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser 1981;17:129–45. PubMed

75.

Schmitz SD. Die Rolle der Mastzelle beim überschießenden Wachstum traumatisierter dermaler Neurofibrome. Dissertation, Berlin 2009.

76.

Bornstein J, Cohen Y, Zarfati D, Sela S, Ophir E. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int J Gynecol Pathol 2008;27:136–41. CrossRefPubMed

77.

Afrin L. Presentation, diagnosis, and management of mast cell activation syndrome. In Mast Cells: Phenotypic features, biological functions, and role in immunity. Nova Science Publishers, Happauge, NY, 2013: pp. 155–231.

78.

Iriarte LM, Mateu J, Cruz G, Escudero J. Chorea: A new manifestation of mastocytosis. J Neurol Neurosurg Psychiatry 1988;51:1457–63. PubMedCentralCrossRefPubMed

79.

Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade’s clinical experience at the brigham and the women’s hospital. Invest Dermatol 1991;96:5S–14S. CrossRef

80.

Theoharides TC, Zhang B. Neuro-inflammation, blood-brain barrier, seizures and autism. J Neuroinflammation 2011;8:168. PubMedCentralCrossRefPubMed

81.

Dasanu CA, Davis LK, Bauer F. Aleukemic leukemia presenting with paranoid psychosis. Conn Med 2013;77:537–9. PubMed

82.

Undem BJ, Taylor-Clark T. Mechanisms underlying the neuronal-based symptoms of allergy. J Allergy Clin Immunol 2014;133:1521–34. CrossRefPubMed

83.

Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435–53. CrossRefPubMed

84.

Yuan H, Zhu X, Zhou S, Chen Q, Zhu X, Ma X, He X, Tian M, Shi X. Role of mast cell activation in inducing microglial cells to release neurotrophin. J Neurosci Res 2010;88:1348–54. PubMed

85.

Schramm A, Grunewald S, Lorenz R, Classen J, Naumann M. Parkinsonism due to bilateral basal ganglia lesions following mastocytosis-induced hypoxia. J Neurol 2004;251:1270–2. CrossRefPubMed

86.

Berlin G, Enerbäck L. Non-differential inhibition of histamine and serotonin release from mast cells by amitriptyline. Agents Actions 1986;18:89–91. CrossRefPubMed

87.

Sano T, Uchida MK, Suzuki-Nishimura T. The effects of clozapine on rat mast cells are different from those of benzodiazepines. Gen Pharmacol 1990;21:559–61. CrossRefPubMed

88.

Seol IW, Kuo NY, Kim KM. Effects of dopaminergic drugs on the mast cell degranulation and nitric oxide generation in RAW 264.7 cells. Arch Pharm Res 2004;27:94–8. CrossRefPubMed

89.

Laengle UW, Markstein R, Pralet D, Seewald W, Roman D. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist an dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. Exp Eye Res 2006;83:1335–9. CrossRefPubMed

90.

De Filippis D, D’Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 2008;20 Suppl 1:20–5. CrossRefPubMed

91.

Shimoda T, Liang Z, Suzuki H, Kawana S. Inhibitory effects of antipsychotic and anxiolytic agents on stress-induced degranulation of mouse dermal mast cells. Clin Exp Dermatol 2010;35:531–6. CrossRefPubMed

92.

Indraccolo U, Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations. Eur J Obstet Gynecol Reprod Biol 2010;150:76–9. CrossRefPubMed

93.

Joks R, Durkin HG. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol Res 2011;64:602–9. CrossRefPubMed

94.

Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 2012;5:437–42. PubMedCentralCrossRefPubMed

95.

Bastos LF, de Oliveira AC, Watkins LR, Moraes MF, Coelho MM. Tetracyclines and pain. Naunyn Schmiedebergs Arch Pharmacol 2012;385:225–41. CrossRefPubMed

96.

Grotenhermen F, Müller-Vahl K. Das therapeutische Potenzial von Cannabis und Cannabnoiden. Dtsch Arztebl Int 2012;109:495–501. PubMedCentralPubMed

97.

Oliva SU, Scarano WR, Okada FK, Miraglia SM. Harmful effects of carbamazepine on the postnatal development of the rat ventral prostate. Reprod Biol Endocrinol 2012;10:22. PubMedCentralCrossRefPubMed

98.

Hu LY, Liu CJ, Lu T, Hu TM, Tsai CF, Hu YW, Shen CC, Chang YS, Chen MH, Teng CJ, Chiang HL, Yeh CM, Su VY, Wang WS, Chen PM, Chen TJ, Su TP. Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study. PLoS One 2013;8:e80064. PubMedCentralCrossRefPubMed

99.

Ferjan I, Lipnik-Štangelj M. Chronic pain treatment: the influence of tricyclic antidepressants on serotonin release and uptake in mast cells. Mediators Inflamm 2013;2013:340473. PubMedCentralPubMed

100.

Gurgel JA, Lima-Júnior RC, Rabelo CO, Pessoa BB, Brito GA, Ribeiro RA. Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation. Rev Bras Psiquiatr 2013;35:387–92. CrossRefPubMed

Titel: Vermutlich oft gesehen, aber nur selten diagnostiziert
Neurologische und psychiatrische Symptome der systemischen MCAD
Autoren:: Dr. med. Dieter Pöhlau
Prof. Dr. med. Martin Raithel
PD Dr. rer. nat. Britta Haenisch
Dipl.-Phys. Sabrina Harzer
Prof. Dr. med. Gerhard J. Molderings
Publikationsdatum: 08.09.2015
DOI: https://doi.org/10.1007/s15016-015-0694-0
Verlag: Urban & Vogel
Zeitschrift: NeuroTransmitter
Ausgabe 9/2015
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397

Neu im Fachgebiet Neurologie

17.02.2020 | Neurologische Diagnostik | Nachrichten

Neurologische und psychiatrische Symptome der systemischen MCAD

Interessenkonflikt

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Kinder mit Immunenzephalitiden oft MOG-positiv

Prävention von familiärer Alzheimerdemenz gescheitert

Obligatorische PJ-Vergütung! Das fordern Marburger Bund und bvmd

Kriterien für Schmerzassessment oft unbrauchbar – außer diese vier

Neurologie Fragen und Antworten

Nervenkompressionssyndrome

Newsletter

Springer Medizin

Interessenkonflikt

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

fMRT zeigt: Ein Teil des Bewusstseins kann auch im Wachkoma erhalten sein

Dritte Fortbildung zur EVA-NP startet im März 2016

Morbus Parkinson: Schmerzbekämpfung mit Fixkombination

Farbwelten

Lebensverlängernde oder -verkürzende Maßnahmen bei ALS-Patienten

Der Wahnsinn liegt auf der Lauer

Neu im Fachgebiet Neurologie

Kinder mit Immunenzephalitiden oft MOG-positiv

Prävention von familiärer Alzheimerdemenz gescheitert

Obligatorische PJ-Vergütung! Das fordern Marburger Bund und bvmd

Kriterien für Schmerzassessment oft unbrauchbar – außer diese vier

Meistgelesene Bücher in der Neurologie

Neurologie Fragen und Antworten

Nervenkompressionssyndrome

Newsletter